Navigation Links
Glycominds and Fox Chase Cancer Center Announce a Collaboration to Discover New Cancer Detection Diagnostic Tests
Date:10/25/2007

LOD, Israel, October 25 /PRNewswire/ -- Glycominds Ltd., a bio-diagnostics company specializing in glycan biomarkers for diagnosis and disease management of autoimmune diseases and cancer, announced today entering into a research agreement with Fox Chase Cancer Center (FCCC), an NCI designated cancer center to develop a new diagnostics blood test for breast cancer.

"We are very pleased to work with FCCC on this project," stated Dr. Nir Dotan, Glycominds' co-founder, CTO and VP R&D. "Glycominds' anti-glycan antibodies biomarkers approach together with the FCCC excellent patient records, samples and clinical know-how give this project a high basis for success."

"Glycominds' glycan biomarker technology stands out as innovative and unique. We hope that just as Glycominds was able to successfully develop new diagnostic and prognostic biomarkers for Autoimmune disorders, we will be able to identify glycans that can be useful in the early detection of cancer," stated Dr. Andrew K. Godwin, FCCC's Director of the Clinical Molecular Genetics Laboratory and the Biosample Repository . "I believe that glycan technology has the potential to enhance the early diagnosis of breast cancer and improve the health and quality of life for millions of women."

About Glycominds Ltd.

Glycominds Ltd. is a biodiagnostics company specialized in developing and commercializing glycan biomarkers, a new class of early diagnostic and prognostic tests based on complex sugar molecules for the detection and management of autoimmune diseases and cancer. The company's goal is to provide physicians with tools that improve treatment selection in autoimmune diseases and early detection of cancers.

Glycominds lead product, IBDX(R), a blood test for early diagnosis of Inflammatory Bowel Disease (IBD) and the prognosis of Crohn's disease severity is commercialized in Israel and Europe, with a U.S. launch planned in early 2008. The Company's gMS(TM) Dx, a blood test for early diagnosis of Multiple Sclerosis (MS), and gMS(TM) PRO, a prognostic test for MS activity, are also expected to enter the market in 2008. Glycominds' other pipeline products include blood tests for the prediction of recurrent pregnancy loss based on hyper-coagulation caused by antiphoshpholipids syndrome (APS), and first-in-class screening tests for breast and colorectal cancers. http://www.glycominds.com

For more information, please contact:

Glycominds, Ltd.

Dr. Avinoam Dukler

Chief Executive Officer

dukler@glycominds.com

The Ruth Group

Sara Ephraim (investors)

Phone: +1-646-536-7002

sephraim@theruthgroup.com

Janine McCargo (media)

Phone: +1-646-536-7033

jmccargo@theruthgroup.com


'/>"/>
SOURCE Glycominds Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Purchase of Madison broadband network may bring improved service
2. Wisconsin fares slightly better in venture capital chase
3. Metavante completes purchase of check processing firm
4. Logicalis purchases Solution Technology for $90M
5. Merge eFilm announces stock repurchase plan
6. Wisconsin based Graphics Distribution, Inc. purchased by Florida company
7. GE Medicals Acquisitions May Prompt More Purchases
8. Green Bay Software Company Purchased by GE
9. Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer
10. Cancer siRNA Oligo Set Version 1.0
11. Cancer-Related miRNAs Uncovered by the mirVana miRNA Microarray Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Sequenom, Inc. (NASDAQ: SQNM ... lives through the development of innovative products and services, ... the United States denied its petition to ... of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") are ... by the Supreme Court,s Mayo Collaborative Services v. Prometheus ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016  The American College of Medical ... Show Executive Magazine as one of the fastest-growing trade ... 25-27 at the Bellagio in Las Vegas ... highest percentage of growth in each of the following categories: ... companies and number of attendees. The 2015 ACMG Annual Meeting ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
Breaking Biology News(10 mins):